Hence, antagonizing these antiapoptotic proteins is considered a reasonable approach to prevent cancer progression, where apoptosis inducers such as BH3‐mimetics act as effective anticancer drugs through specific binding to the hydrophobic groove of BCL‐2 antiapoptotic proteins [7]. This evidence concerns the gene BCL2 and cancer.